The Pocket Book is for use by doctors nurses and other health workers who are responsible for the care of young children at the first level referral hospitals. This second edition is based on evidence from several WHO updated and published clinical guidelines. It is for use in both inpatient and outpatient care in small hospitals with basic laboratory facilities and essential medicines. In some settings these guidelines can be used in any facilities where sick children are admitted for inpatient care. The Pocket Book is one of a series of documents and tools that support the Integrated Managem.

Serves as a ready-reckoner of drug dosages for young residents and practising pediatricians which will instil confidence in their prescribing abilities and reduce the incidence of avoidable side effects of drugs. It provides brief Information on the pharmacokinetics of drugs with an emphasis on the advantages and disadvantages of various routes of administration, drug absorption, distribution, bioavailabillty, tissue binding, half-life and metabolism and excretion. The drugs have been listed alphabetically with dally dosages per unit body weight, frequency, and route of administration. Important cautions, contraindications and adverse effects of selected drugs have been provided. Trade names of formulations from standard pharmaceutical companies along with their products and strengths are also given.

This is an updated and expanded edition of the popular pocketbook aimed to serve the needs of medical students, resident doctors, general practioners, and consultant pediatricians. Several newer formulations including antiretroviral agents, antimalarias, and antibiatics have been Included. The standard or usual adult doses of most of the drugs are also provided. The book also serve as a ready-reckoner of drug dosages to young residents and practising pediatricians, and will intial confidence In their prescriptions and reduce the Incidence of avoidable side effects of drugs. It provides brief Information on the pharmacokinetics of drugs with emphasis on advantages and disadvantages of various routes of administration, drug absorption, distribution, bioavailabillty, tissue binding, half-life and metabolism and excretion. The drugs have been listed alphabetically dally dosages per unit body weight, frequency and route of administration. Important cautions, contraindications and adverse effects of selected drugs have been provided. Trade names of formulations from standard pharmaceutical companies along with their products and strengths are also given.

Focused on pediatric physiology, pharmacology, pharmacokinetics and pharmacodynamics, this book illustrates the differences between the pediatric population and adults; knowledge of extreme importance not only during pediatric drug development but also in the clinical practice. Physicians, nurses, clinical pharmacologists, researchers and healthcare professionals will find this an invaluable resource. With the advent of pediatric exclusivity, and requirements to conduct clinical studies in children, an emphasis has been placed on finding a safe and efficacious dose of a drug in children. Children are not ‘small adults’, and drug dosing in this population requires special consideration. There are subtle physiological and biochemical differences among neonates, infants, children, adolescents and adults and dosing in pediatrics requires proper understanding of these factors. Furthermore, dosing in children, as in adults, should be based on pharmacokinetic and pharmacodynamic data. This is an evolving area, as pediatric pharmacokinetic studies are becoming mandatory for getting approval of new drugs in this population.

The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) were designed to encourage more pediatric studies of drugs used for children. The FDA asked the IOM to review aspects of pediatric studies and changes in product labeling that resulted from BPCA and PREA and their predecessor policies, as well as assess the incentives for pediatric studies of biologics and the extent to which biologics have been studied in children. The IOM committee concludes that these policies have helped provide clinicians who care for children with better information about the efficacy, safety, and appropriate prescribing of drugs. The IOM suggests that more can be done to increase knowledge about drugs used by children and thereby improve the clinical care, health, and well-being of the nation's children.

This manual gives information on the causative organisms, epidemiology and clinical features of all important childhood infections. It includes guidance on the clinical management of the infections and on steps to be taken to prevent future cases.